Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBIRC6)

Drug Name
3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM Drug Info
Synonyms
Methylene Blue cation; 3,7-bis(dimethylamino)phenothiazin-5-ium; UNII-ZMZ79891ZH; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium; ZMZ79891ZH; CHEBI:43830; azul de metileno; Methylthionine HCl; Methylthionine chloride; CHEMBL405110; NSC3089; NSC617593; NSC215213; NCGC00167496-03; NCGC00167496-01; C.I. 52015; Methylthioninium; Methylene Blue parent; AI3-52463; cid_6099; AC1Q4UZ6; AC1L1HI1; SCHEMBL109755; CHEMBL191083; DTXSID3047009; NOCAS_47009; RBTBFTRPCNLSDE-UHFFFAOYSA-N; MolPort-003-700-760
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4139
ChEBI ID
CHEBI:43830
CAS Number
CAS 7060-82-4
TTD Drug ID
DMBIRC6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Acetylcholinesterase (AChE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [2]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [3]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [4]
Galantamine DMEO794 Alzheimer disease 8A20 Approved [5]
Huperzine A DMMAWLU Alzheimer disease 8A20 Approved [6]
Neostigmine DM6T2J3 Myasthenia gravis 8C6Y Approved [7]
YM443 DMNZCI1 Functional dyspepsia DD90.3 Approved [8]
Ambenonium DMOP0BL Myasthenia gravis 8C6Y Approved [9]
Demecarium bromide DMAYEU1 Open-angle glaucoma 9C61 Approved [10]
Isoflurophate DMBSK7X Glaucoma/ocular hypertension 9C61 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [1]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
4 Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
5 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
6 Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
7 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
10 The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
11 Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.